Idarucizumab Intravenous for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Consultant approval required as high cost drug
This is not a blood product, and does not require Consultant Haematologist approval
Supply available in pharmacy: Fridge 2, Shelf 10
Idarucizumab binds specifically to dabigatran and reverses its anticoagulant effect. It will not reverse the effects of other anticoagulants
In order to improve the traceability of biological medicinal products, the name and batch number of the administered product should be clearly recorded
Precautions need to be taken during administration to prevent possible air embolism - particularly in central line administration. Bottles must be vented in one of two ways: directly by means of a filter needle into the bottle which goes through the rubber stopper and opens into the air, or direct air vent on the air inlet of the administration set, located between the drip chamber and piercing pin, it is covered with a bacterial retentive filter to reduce the chance of contamination

Praxbind 2.5g per 50ml vial

Already in solution

Not required- product ready for infusion

Gloves, protective eyewear and a mask should be worn by those handling this drug ^{(ref 2)}

Intermittent intravenous infusion (preferred method)

Administer a 5g dose as two consecutive infusions of 2.5g per 50ml over 5 to 10 minutes each
The residual volume in the infusion line must be flushed through at the same rate to avoid significant underdosing

Bolus intravenous injection - see under further information

Usual dose

Repeat doses^{(ref 1)}

A second dose of 5g is unlikely to be required, except in the case of dabigatran overdose
Administration of a second 5g dose may be considered in the following situation: if both Thrombin time and aPTT are prolonged post administration. This is to be discussed with Haematology

Renal or hepatic impairment

Relevant coagulation parameters are activated Partial Thromboplastin Time (aPTT) and Thrombin time (TT)
Additional testing as per Haematology (ref 1)

The manufacturers suggest that the drug may be given as a bolus injection (as an alternative to a short infusion) - however, we feel that the infusion method is preferable due to the volume (100ml per dose) involved.
Reversal effects are usually evident immediately after administration (plasma concentrations of unbound dabigatran reduced by more than 99%)
The majority of patients (>90%) showed sustained reversal of dabigatran plasma concentrations. In a subset of patients, recurrence of plasma levels of unbound dabigatran and concomitant elevation of clotting tests was observed, possibly due to redistribution of dabigatran from the periphery. This occurred 1 to 24 hours after administration of idarucizumab mainly at time points of 12 hours or more. The presence of a normal thrombin time excludes the presence of dabigatran. Patients who are bleeding may develop coagulopathies for other reasons other than the presence of the drug, and this should be borne in mind if repeat administration is being considered ^{(ref 1)}
Dabigatran can be re-initiated 24 hours after administration of idarucizumab, if the patient is clinically stable and adequate haemostasis has been achieved

Store between 2 and 8⁰C
Do not freeze
Prior to use, the unopened vial may be kept at room temperature (up to 30⁰C) for up to 48 hours, if stored in the original package in order to protect from light

SPC 17th Sept 2020

1: Specialist opinion Dr Ruth Gilmore, Consultant Haematologist, GUH 29/03/2022

2:Clinical Oncology Society of Australia. Position statement: safe handling of monoclonal antibodies in healthcare settings September 2013

Reversal agent for dabigatran ONLY (monoclonal antibody fragment)